Cómo citar
Resumen
En la Diabetes Mellitus tipo 1, la terapia intensiva con insulina es la primera línea de tratamiento. Los inhibidores del cotransportador sodio glucosa – 2 son fármacos con un mecanismo de acción no insulínico que se han estudiado en estos pacientes como primer medicamento vía oral para la enfermedad. Se realizó una revisión de estudios originales que analizaran el papel de éstos fármacos en coadyuvancia con insulina para el manejo de la diabetes mellitus tipo 1 en adultos, con el propósito de determinar su eficacia y serguridad. Los resultados de esta revisión incluyeron una disminución estable de la hemoglobina A glucada, pérdida de peso y disminución en la dosis diaria de insulina, con un aumento en la incidencia de cetoacidosis diabética.
Palabras clave
Citas
American Diabetes Association. 5. Lifestyle Management: Standards of Medical Care in Diabetes 2019. Diabetes Care. enero de 2019;42(Supplement 1):S46-60.https://doi.org/10.2337/dc19-S005
Akturk HK, Rewers A, Garg SK. SGLT inhibition. Current Opinion in Endocrinology & Diabetes and Obesity. 2018 08;25(4):246-250. https://doi.org/10.1097/med.0000000000000423
Actualización en diabetes tipo 1. En Madrid: Academia Española de Pediatría[Internet] 2019[Consultado 20 Jul 2019] p. 445-451. Disponible en: https://www.aepap.org/sites/default/files/pags._445-452_actualizacion_en_diabetes.pdf
Fattah H, Vallon V. The Potential Role of SGLT2 Inhibitors in the Treatment of Type 1 Diabetes Mellitus. Drugs. 2018;78(7):717-726. https://doi.org/10.1007/s40265-018-0901-y
Sanofi / Lexicon Pharmaceuticals. Sotagliflozin as an Adjunct to Insulin for Type 1 Diabetes Endocrinologic and Metabolic Drugs Advisory Committee [Internet]. 2019. CO-1 – AA-15 Disponible en: https://www.fda.gov/media/121288/download
Maddipatla M, Mathias T. FDA rejects Sanofi-Lexicon add-on pill for type 1 diabetes [Internet]. Reuters United States; Disponible en: https://www.reuters.com/article/us-sanofi-fr-fda/fda-rejects-sanofi-lexicon-add-on-pill-for-type-1-diabetes-idUSKCN1R32DM
European Medicines Agency. First oral add-on treatment to insulin for treatment of certain patients with type 1 diabetes [Internet]. 2019. Disponible en: https://www.ema.europa.eu/en/news/first-oral-add-treatment-insulin-treatment-certain-patients-type-1-diabetes
Kalra S. Sodium Glucose Co-Transporter-2 (SGLT2) Inhibitors: A Review of Their Basic and Clinical Pharmacology. Diabetes Ther. diciembre de 2014;5(2):355-366. https://doi.org/10.1007/s13300-014-0089-4
Fitchett D, Inzucchi SE, Cannon CP, McGuire DK, Scirica BM, Johansen OE, et al. Empagliflozin Reduced Mortality and Hospitalization for Heart Failure Across the Spectrum of Cardiovascular Risk in the EMPA-REG OUTCOME Trial. Circulation. el 12 de marzo de 2019;139(11):1384-1395. https://doi.org/10.1161/CIRCULATIONAHA.118.037778
Perkins BA, Cherney DZ, Partridge H, Soleymanlou N, Tschirhart H, Zinman B, Fagan NM, Kaspers S, Woerle H, Broedl UC, Johansen O. Sodium-Glucose Cotransporter 2 Inhibition and Glycemic Control in Type 1 Diabetes: Results of an 8-Week Open-Label Proof-of-Concept Trial. Diabetes Care. 2014 03 04;37(5):1480-1483. https://doi.org/10.2337/dc13-2338
Sands AT, Zambrowicz BP, Rosenstock J, Lapuerta P, Bode BW, Garg SK, et al. Sotagliflozin, a Dual SGLT1 and SGLT2 Inhibitor, as Adjunct Therapy to Insulin in Type 1 Diabetes. Diabetes Care. julio de 2015;38(7):1181-1188. https://doi.org/10.2337/dc14-2806
Henry RR, Thakkar P, Tong C, Polidori D, Alba M. Efficacy and Safety of Canagliflozin, a Sodium-Glucose Cotransporter 2 Inhibitor, as Add-on to Insulin in Patients With Type 1 Diabetes. Diabetes Care. diciembre de 2015;38(12):2258-2265. https://doi.org/10.2337/dc15-1730
Dandona P, Mathieu C, Phillip M, Hansen L, Griffen SC, Tschöpe D, et al. Efficacy and safety of dapagliflozin in patients with inadequately controlled type 1 diabetes (DEPICT-1): 24 week results from a multicentre, double-blind, phase 3, randomised controlled trial. The Lancet Diabetes & Endocrinology. 2017 Nov;5(11):864-876. https://doi.org/10.1016/s2213-8587(17)30308-x
Buse JB, Garg SK, Rosenstock J, Bailey TS, Banks P, Bode BW, Danne T, Kushner JA, Lane WS, Lapuerta P, McGuire DK, Peters AL, Reed J, Sawhney S, Strumph P. Sotagliflozin in Combination With Optimized Insulin Therapy in Adults With Type 1 Diabetes: The North American inTandem1 Study. Diabetes Care. 2018 06 24;41(9):1970-1980. https://doi.org/10.2337/dc18-0343
Yang Y, Yang Y, Pan H, Wang B, Chen S, Zhu H, Pan H, Wang B, Chen S, Zhu H. Efficacy and Safety of SGLT2 Inhibitors in Patients with Type 1 Diabetes: A Meta-analysis of Randomized Controlled Trials. Chinese Medical Sciences Journal. 2017;32(1):22-27. https://doi.org/10.24920/j1001-9242.2007.003
El Masri D, Ghosh S, Jaber LA. Safety and efficacy of sodium-glucose cotransporter 2 (SGLT2) inhibitors in type 1 diabetes: A systematic review and meta-analysis. Diabetes Research and Clinical Practice. 2018 03;137:83-92. https://doi.org/10.1016/j.diabres.2018.01.004
Riddle MC, Cefalu WT. SGLT Inhibitors for Type 1 Diabetes: An Obvious Choice or Too Good to Be True? Diabetes Care. diciembre de 2018;41(12):2444-2447. https://doi.org/10.2337/dci18-0041